Pops as Weight-Loss Drug Data from Rival Novo Nordisk Disappoints

tipranks.com/news/eli-lilly-stock-lly-pops-as-weight-loss-drug-data-from-rival-novo-nordisk-disappoints

Eli Lilly’s (LLY) stock is marching higher on news that rival Novo Nordisk (NVO) has issued data on its newest weight-loss drug candidate that disappointed.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment…

This story appeared on tipranks.com, 2025-06-23 21:49:26.966000.
The Entire Business World on a Single Page. Free to Use →